Clinical Trial Tracker
Compound, condition, sponsor, registry, country, status, design, population, outcomes, and posted results.
Trackers
Trackers
The field changes too quickly for static articles alone. Each tracker records source type, confidence, last checked date, and unresolved questions.
Policy Tracker
Federal, state, international, bills, agency guidance, public funding, hearings, and bill text.
Clinic Claims Tracker
Public clinic claims, locations, safety statements, outcome language, adverse-event signals, and referral-free source notes.
Podcast and Interview Tracker
Podcast episodes, YouTube interviews, documentaries, panels, radio, guests, claims, summaries, and source links.
Adverse Event Tracker
Case reports, deaths, emergency transfers, rhythm events, interaction concerns, and causality limits.
Conservation and Sourcing Tracker
Plant pressure, poaching risk, cultivation, benefit sharing, Gabonese context, and sourcing claims.
Companies and commercial development
Source-labeled company records tracked in the commercial lane. Business claims and financing do not establish clinical value.
CompanyConfidence: Moderate
Commercial development
atai Life Sciences
atai is a major psychedelic biotech whose ibogaine and noribogaine ventures shape the commercial and analog-development conversation.
- atai Life Sciences is a psychedelic biotech that, in January 2020, announced joint ventures with DemeRx to develop ibogaine and noribogaine for opioid use disorder.
- atai ibogaine activity is a commercial and drug-development signal within the wider psychedelic biotech field, not clinical proof.
- Business milestones and financing news are tracked separately from evidence and are not proof of effectiveness.
What this does not prove: Corporate investment, pipelines, and press releases do not establish clinical value, safety, or approval.
atai/DemeRx joint venture announcement (company release)
Search records →